{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:19:17Z","timestamp":1787771957088,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"\n Purpose:<\/jats:title>\n This study aims to assess the effectiveness and safety of combining the Preserflo\u2122 MicroShunt implant (MicroShunt) with a simultaneous Ologen\u2122 implant in patients with glaucoma.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6\u201315 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 \u00b1 5.8 mmHg to 11.4 \u00b1 2.6 mmHg at 18 months (\n P<\/jats:italic>\n < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 \u00b1 5.2 mmHg to 11.7 \u00b1 2.5 mmHg (\n P<\/jats:italic>\n < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 \u00b1 5.8 mmHg to 10.9 \u00b1 2.7 mmHg (\n P<\/jats:italic>\n = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 \u00b1 1.1 to 0.3 \u00b1 0.7 in the overall study population (\n P<\/jats:italic>\n < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n The combination of Ologen\u2122 and Preserflo\u2122 MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1502_23","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:02:54Z","timestamp":1709078574000},"page":"417-426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting"],"prefix":"10.4103","volume":"72","author":[{"given":"Mar\u00eda","family":"Rojo-Arnao","sequence":"first","affiliation":[{"name":"Glaucoma Department, Hospital Virgen de la Luz, Cuenca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Martinez-de-la-Casa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and ORL, Faculty of Medicine, Ophthalmology Unit, Hospital Clinico San-Carlos, Universidad Complutense de Madrid, Instituto de Investigaci\u00f3n Sanitaria del Hospital Clinico San-Carlos (IdISSC), Madrid, Spain"},{"name":"Department of Immunology, Ophthalmology and ORL, School of Medicine, Instituto de Investigaciones Oftalmologicas Ramon Castroviejo, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Albis-Donado","sequence":"additional","affiliation":[{"name":"Glaucoma Specialist, Private Practice, Visual Sense, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ya\u00f1ez-Castro","sequence":"additional","affiliation":[{"name":"Glaucoma Department, Hospital Virgen de la Luz, Cuenca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Maroto-Cejudo","sequence":"additional","affiliation":[{"name":"Glaucoma Department, Hospital Virgen de la Luz, Cuenca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"T\u00e9llez","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital de la Santa Creu i de Sant Pau, Autonoma University of Barcelona, Barcelona, Spain"},{"name":"Departament of Ophthalmology, Grupo Admiravisi\u00f3n, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Menoyo-Calatayud","sequence":"additional","affiliation":[{"name":"Glaucoma Department, Hospital Virgen de la Luz, Cuenca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","article-title":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition\u2014Chapter 3: Treatment principles and options. Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options","volume":"101","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/01.ijg.0000151684.12033.4d","article-title":"2002 survey of the American Glaucoma Society: Practice preferences for glaucoma surgery and antifibrotic use","volume":"14","author":"Joshi","year":"2005","journal-title":"J Glaucoma"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/ICU.0b013e32834ff1e7","article-title":"Micro-invasive glaucoma surgery: current perspectives and future directions","volume":"23","author":"Saheb","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ajo.2005.02.013","article-title":"Perioperative complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS)","volume":"140","author":"Jampel","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ophtha.2019.10.002","article-title":"Treatment outcomes in the primary tube versus trabeculectomy study after 3 years of follow-up","volume":"127","author":"Gedde","year":"2020","journal-title":"Ophthalmology"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/bjophthalmol-2021-319062","article-title":"Effect of COVID-19 pandemic on glaucoma surgical practices in the UK","volume":"106","author":"Holland","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"36.","DOI":"10.1186\/s40662-019-0162-1","article-title":"Ab externo implantation of the MicroShunt, a poly (styrene- block-isobutylene- block-styrene) surgical device for the treatment of primary open-angle glaucoma: A review","volume":"6","author":"Sadruddin","year":"2019","journal-title":"Eye Vis (Lond)"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"e85782.","DOI":"10.1371\/journal.pone.0085782","article-title":"Ologen implant versus mitomycin C for trabeculectomy: A systematic review and meta-analysis","volume":"9","author":"He","year":"2014","journal-title":"PLoS One"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"3178.","DOI":"10.1038\/s41598-019-38656-x","article-title":"Efficacy of Ologen matrix implant in Ahmed glaucoma valve implantation","volume":"9","author":"Sastre-Ib\u00e1\u00f1ez","year":"2019","journal-title":"Sci Rep"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"72.","DOI":"10.1186\/s12886-021-01827-4","article-title":"Ologen augmentation of Ahmed glaucoma drainage devices in pediatric glaucomas","volume":"21","author":"Jacobson","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"33.","DOI":"10.1186\/s40662-021-00253-3","article-title":"Preliminary results of Preserflo Microshunt versus Preserflo Microshunt and Ologen implantation","volume":"8","author":"Vastardis","year":"2021","journal-title":"Eye Vis (Lond)"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40123-021-00428-0","article-title":"Corneal endothelial cell loss after PRESERFLO\u2122 MicroShunt implantation in the anterior chamber: Anterior segment OCT tube location as a risk factor","volume":"11","author":"Ibarz-Barber\u00e1","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11121-016-0644-5","article-title":"Principled missing data treatments","volume":"19","author":"Lang","year":"2018","journal-title":"Prev Sci"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"e0024","DOI":"10.5041\/RMMJ.10345","article-title":"Evolution of glaucoma surgery in the last 25 years","volume":"9","author":"Bar-David","year":"2018","journal-title":"Rambam Maimonides Med J"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jfo.2015.05.005","article-title":"R\u00e9sultats \u00e0 un an de l\u2019efficacit\u00e9 et de l\u2019innocuit\u00e9 du MicroShunt InnFocus selon l\u2019emplacement et la concentration de MMC [One-year results on the safety and efficacy of the InnFocus MicroShunt\u2122 depending on placement and concentration of mitomycin C]","volume":"38","author":"Riss","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/IJG.0000000000000368","article-title":"Three-Year follow-up of a novel aqueous humor MicroShunt","volume":"25","author":"Batlle","year":"2016","journal-title":"J Glaucoma"},{"key":"R17-20260504","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1111\/aos.14602","article-title":"XEN\u00ae<\/sup>Gel Stent compared to PRESERFLO\u2122 MicroShunt implantation for primary open-angle glaucoma: Two-year results","volume":"99","author":"Scheres","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/IJG.0000000000001734","article-title":"Long-term results of the PRESERFLO MicroShunt in patients with primary open-angle glaucoma from a single-center nonrandomized study","volume":"30","author":"Batlle","year":"2021","journal-title":"J Glaucoma"},{"key":"R19-20260504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajo.2020.02.020","article-title":"Intermediate outcomes of a novel standalone Ab Externo SIBS microshunt with mitomycin C","volume":"215","author":"Schlenker","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"15600.","DOI":"10.1038\/s41598-021-95217-x","article-title":"Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients","volume":"11","author":"Mart\u00ednez-de-la-Casa","year":"2021","journal-title":"Sci Rep"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s12325-021-01811-w","article-title":"Efficacy and safety of PreserFlo\u00ae MicroShunt after a failed trabeculectomy in eyes with primary open-angle glaucoma: A retrospective study","volume":"38","author":"Quaranta","year":"2021","journal-title":"Adv Ther"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ogla.2021.08.005","article-title":"Effectiveness of MicroShunt in patients with primary open-angle and pseudoexfoliative glaucoma: A Retrospective European multicenter study","volume":"5","author":"Fea","year":"2022","journal-title":"Ophthalmol Glaucoma"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ogla.2021.07.008","article-title":"Safety and effectiveness of the PRESERFLO\u00ae MicroShunt in primary open-angle glaucoma: Results from a 2-year multicenter study","volume":"5","author":"Beckers","year":"2022","journal-title":"Ophthalmol Glaucoma"},{"key":"R24-20260504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/IJG.0000000000002052","article-title":"Efficacy and safety of the Preserflo microshunt with mitomycin C for the treatment of open angle glaucoma","volume":"31","author":"Ibarz Barber\u00e1","year":"2022","journal-title":"J Glaucoma"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41433-022-01995-7","article-title":"Short-term safety and efficacy of Preserflo\u2122 Microshunt in glaucoma patients: A multicentre retrospective cohort study","volume":"37","author":"Bhayani","year":"2023","journal-title":"Eye (Lond)"},{"key":"R26-20260504","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(16)30956-4","article-title":"Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): A randomised controlled trial","volume":"388","author":"Azuara-Blanco","year":"2016","journal-title":"Lancet"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1502_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:22:33Z","timestamp":1787768553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1502_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1502_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"assertion":[{"value":"2023-06-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}